TrialThe British journal of dermatology2021

Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2).

A Wollenberg et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.